Technology
Explore the proprietary technologies that power our innovative therapeutic solutions.
The Innostem Advantage
Discover the proprietary technologies that give Innostem Bio a competitive edge in the field of regenerative medicine.
100x More Efficient
High-Efficiency Stem Cell Isolation
Our proprietary stepwise stem cell isolation and culture technology allows for 100 times efficiency of conventional methods.
- Tissue-Resident Stem Cell Platform
- Integrated homeostasis-mimicking process
- Higher & consistent yield
>3 Year Shelf-Life
Cryopreserved 'Off-the-Shelf' Formulation
Our xeno-free, serum-free cryopreservation technology ensures our allogeneic cell therapeutics are ready for injection post-thaw and stable for over 3 years.
- >80% cell viability post-thaw
- No post-thaw purification needed
- Ready for immediate injection
- Compliant with USP/KP standards
1000+ Doses / Donor
Industrial-Scale Cell Banking
Our high-potency MCB & WCB cell banks, derived from a single donor, can manufacture over 1,000 doses of therapeutic material with consistent quality and stable QC.
- Pharmaceutical-grade cGMP facility
- Consistent potency and quality
- Diverse library of stem cells
Next-Gen Stem Cell Therapy, Redefined
Our next-generation platform overcomes the limitations of traditional stem cell therapies.
| Feature | Traditional Therapy | Innostem Bio Therapy |
|---|---|---|
| Type | Autologous / Allogeneic | Allogeneic |
| Origin | Bone marrow, Fat, Cord Blood | Peripheral Nerve / Myocardium |
| Manufacture Quantity (/Donor) | One-time or <100 doses | >1,000-10,000 doses |
| Quality Control | Relative difficulty | Stable QC/QA via cell bank |
| Potency | High Variation | Uniform |
| Mechanism of Action | General | Disease-specific mode of action |
| Shelf Life | 24-48 hours (Refrigeration) | >3 years (Cryopreserved Formula)) |
| Dosage | Single Dosing | Ensuring repeated dosing with same lots |
Type
Traditional Therapy
Autologous / Allogeneic
Innostem Bio Therapy
Allogeneic
Origin
Traditional Therapy
Bone marrow, Fat, Cord Blood
Innostem Bio Therapy
Peripheral Nerve / Myocardium
Manufacture Quantity (/Donor)
Traditional Therapy
One-time or <100 doses
Innostem Bio Therapy
>1,000-10,000 doses
Quality Control
Traditional Therapy
Relative difficulty
Innostem Bio Therapy
Stable QC/QA via cell bank
Potency
Traditional Therapy
High Variation
Innostem Bio Therapy
Uniform
Mechanism of Action
Traditional Therapy
General
Innostem Bio Therapy
Disease-specific mode of action
Shelf Life
Traditional Therapy
24-48 hours (Refrigeration)
Innostem Bio Therapy
>3 years (Cryopreserved Formula))
Dosage
Traditional Therapy
Single Dosing
Innostem Bio Therapy
Ensuring repeated dosing with same lots
Patent Portfolio
Our intellectual property is a testament to our commitment to innovation and leadership in regenerative medicine.
| Title | Application Number | Application Date | Registration Number | Registration Date |
|---|---|---|---|---|
| Therapeutic Composition for Adipose Tissue Disorders, and Methods for Its Preparation and Delivery | KR 10-0811537 | 2008-03-03 | ||
| Method for Culturing Cardiac Progenitor Cells and Therapeutic Applications Thereof | KR 10-1389850 | 2014-04-22 | ||
| Method for Culturing Neural Crest Stem Cells and Therapeutic Applications Thereof | KR 10-1389851 | 2014-04-22 | ||
| EP 2 845 898 | 2017-07-05 | |||
| Method for the Culture of Skeletal Muscle Stem Cells and Uses Thereof | KR 10-1389852 | 2014-04-22 | ||
| Method for Culturing Mesenchymal Stem Cells Derived from the Gastrointestinal Tract, Peripheral Nerves, or Blood Vessels, and Uses Thereof | KR 10-1389849 | 2014-04-22 | ||
| Mesenchymal Stem Cells Derived from the Synovial Membrane and Uses Thereof | KR 10-2223043 | 2021-02-25 | ||
| Method for Manufacturing Peripheral Nerve-Mimicking Microtissue and Uses Thereof | KR 10-2322635 | 2021-11-01 | ||
| PCT/KR2022/007991 | 2022-06-07 | |||
| US 18/568,851 | 2023-12-11 | |||
| JP 2023-575974 | 2023-12-08 | |||
| CN 202280050845.4 | 2024-01-18 | |||
| Cryopreservation Solution Composition for Long-Term Storage of Cellular Biopharmaceuticals | KR 10-2319110 | 2021-10-25 | ||
| PCT/KR2022/000979 | 2022-01-19 | |||
| Method for Isolating and Culturing Tissue-Resident uPAR+/Nestin+ Stem Cells and Uses Thereof | KR 10-2476348 | 2022-12-06 | ||
| PCT/KR2022/007910 | 2022-06-03 | |||
| US 18/290,155 | 2023-11-10 | |||
| EU 22 816 495.0 | 2023-11-10 | |||
| JP 7678614 | 2025-05-08 | |||
| CN 202280039679.8 | 2023-12-01 | |||
| Tissue-Resident uPAR-Positive Stem Cells and Uses Thereof | KR 10-2022-0167670 | 2022-12-05 | ||
| Method for Manufacturing Stem Cell-Derived Exosomes Through Cell Stretching and Their Applications | KR 10-2023-0169400 | 2023-11-19 | ||
| PCT/KR2024/001283 | 2024-01-26 | |||
| US, Pending | ||||
| JP, Pending | ||||
| CN, Pending |
Therapeutic Composition for Adipose Tissue Disorders, and Methods for Its Preparation and Delivery
Application Number
Application Date
Registration Number
KR 10-0811537
Registration Date
2008-03-03
Method for Culturing Cardiac Progenitor Cells and Therapeutic Applications Thereof
Application Number
Application Date
Registration Number
KR 10-1389850
Registration Date
2014-04-22
Method for Culturing Neural Crest Stem Cells and Therapeutic Applications Thereof
Application Number
Application Date
Registration Number
KR 10-1389851
Registration Date
2014-04-22
Application Number
Application Date
Registration Number
EP 2 845 898
Registration Date
2017-07-05
Method for the Culture of Skeletal Muscle Stem Cells and Uses Thereof
Application Number
Application Date
Registration Number
KR 10-1389852
Registration Date
2014-04-22
Method for Culturing Mesenchymal Stem Cells Derived from the Gastrointestinal Tract, Peripheral Nerves, or Blood Vessels, and Uses Thereof
Application Number
Application Date
Registration Number
KR 10-1389849
Registration Date
2014-04-22
Mesenchymal Stem Cells Derived from the Synovial Membrane and Uses Thereof
Application Number
Application Date
Registration Number
KR 10-2223043
Registration Date
2021-02-25
Method for Manufacturing Peripheral Nerve-Mimicking Microtissue and Uses Thereof
Application Number
Application Date
Registration Number
KR 10-2322635
Registration Date
2021-11-01
Application Number
PCT/KR2022/007991
Application Date
2022-06-07
Registration Number
Registration Date
Application Number
US 18/568,851
Application Date
2023-12-11
Registration Number
Registration Date
Application Number
JP 2023-575974
Application Date
2023-12-08
Registration Number
Registration Date
Application Number
CN 202280050845.4
Application Date
2024-01-18
Registration Number
Registration Date
Cryopreservation Solution Composition for Long-Term Storage of Cellular Biopharmaceuticals
Application Number
Application Date
Registration Number
KR 10-2319110
Registration Date
2021-10-25
Application Number
PCT/KR2022/000979
Application Date
2022-01-19
Registration Number
Registration Date
Method for Isolating and Culturing Tissue-Resident uPAR+/Nestin+ Stem Cells and Uses Thereof
Application Number
Application Date
Registration Number
KR 10-2476348
Registration Date
2022-12-06
Application Number
PCT/KR2022/007910
Application Date
2022-06-03
Registration Number
Registration Date
Application Number
US 18/290,155
Application Date
2023-11-10
Registration Number
Registration Date
Application Number
EU 22 816 495.0
Application Date
2023-11-10
Registration Number
Registration Date
Application Number
Application Date
Registration Number
JP 7678614
Registration Date
2025-05-08
Application Number
CN 202280039679.8
Application Date
2023-12-01
Registration Number
Registration Date
Tissue-Resident uPAR-Positive Stem Cells and Uses Thereof
Application Number
KR 10-2022-0167670
Application Date
2022-12-05
Registration Number
Registration Date
Method for Manufacturing Stem Cell-Derived Exosomes Through Cell Stretching and Their Applications
Application Number
KR 10-2023-0169400
Application Date
2023-11-19
Registration Number
Registration Date
Application Number
PCT/KR2024/001283
Application Date
2024-01-26
Registration Number
Registration Date
Application Number
US, Pending
Application Date
Registration Number
Registration Date
Application Number
JP, Pending
Application Date
Registration Number
Registration Date
Application Number
CN, Pending
Application Date
Registration Number
Registration Date
Published Articles
Explore our peer-reviewed research that validates the efficacy and safety of our groundbreaking technologies.
Ex vivo organ culture of adipose tissue for in situ mobilization of adipose-derived stem cells and defining the stem cell niche
J of Cellular Physiol 2010;224:807
Fibrin matrix-supported three- dimensional organ culture of adipose tissue for selective outgrowth, expansion, and isolation of adipose- derived stem cells
Acta Biomaterialia 2011;7:4109
Adipose-tissue-derived stem cells enhance the healing of ischemic colonic anastomoses
J. Korean Coloproctology 2012;28(3):132
Adipose-derived stem cells on the healing of ischemic colitis: a therapeutic effect by angiogenesis
Int J of Colorectal Dis 2012;27:1437
Effect of stem cells and fibrin concentration on the vascularization of the Medpor orbital implant
Clinical and Experiment Ophthal 2010;38:885
The isolation and in situ identification of MSCs residing in loose connective tissues using a niche-preserving organ culture system
Biomaterials 2012;33:4469
Intra-articular delivery of synovium-resident mesenchymal stem cells via BMP-7-loaded fibrous PLGA scaffolds for cartilage repair
J Control Rel 2019;302:169
A fibrin-supported myocardial organ culture for isolation of cardiac stem cells via the recapitulation of cardiac homeostasis
Biomaterials 2012;48:66
Engineered extracellular microenvironment with a tunable mechanical property for controlling cell behavior and cardiomyogenic fate of cardiac stem
Acta Biomaterialia 2017;50:234
Intracellular transduction of TAT-Hsp27 fusion protein enhancing cell survivaland regeneration capacity of cardiac stem cells in acute myocardial infarction
J Control Rel 2015;215:55
Epicardial delivery of VEGF and cardiac stem cells guided by 3-dimensional PLLA mat enhancing cardiac regeneration and angiogenesis in acute myocardial infarction
J Control Rel 2015;205:218
Characterization of human cardiac mesenchymal stromal cells and their extracellular vesicles compaing with human bone marrow derived mesenchymal stem cells
BMB Rep 2020;53:118
Intracellular-type cryopreservation solution improves the cryopreservation outcome of primary human hepatocytes
Tissue Engineer Regenerative Med 2009;6:909
Peripheral Nerve-Derived Stem Cell Spheroids Induce Functional Recovery and Repair after Spinal Cord Injury in Rodents
Int J of Mol Sci 2021:22;4141
Intramyocardial delivery of human cardiac stem cell spheroids with enhanced cell engraftment ability and cardiomyogenic potential for myocardial infarct repair
J Control Rel 2021:10;499
Co-Administration of Resolvin D1 and Peripheral Nerve-Derived Stem Cell Spheroids as a Therapeutic Strategy in a Rat Model of Spinal Cord Injury
Int J Mol Sci 2023;24:10971
Repeated intrathecal injections of peripheral nerve-derived stem cell spheroids improve outcomes in a rat model of traumatic brain injury
Stem Cell Res Ther 2024:15;314